BioNTech (NASDAQ: BNTX) AGM approves all items, oncology push, buyback and 2026 guidance
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
BioNTech SE reported that shareholders approved all agenda items at the 2026 Annual General Meeting, with around 92% of share capital represented. The Supervisory Board was expanded from six to eight members and two new oncology-focused experts, Prof. Iris Löw‑Friedrich and Dr. Susanne Schaffert, were elected alongside extensions for three existing members.
Management emphasized a strategy pivot toward the growing late‑stage oncology pipeline while maintaining infectious disease programs. For 2025, BioNTech posted IFRS revenues of €2,870 million, above its €2,600–2,800 million guidance range. In Q1 2026, revenues were €118 million and cash, cash equivalents and security investments totaled €16.8 billion, supporting continued R&D investment.
The company reaffirmed 2026 non‑IFRS revenue guidance of €2,000–2,300 million, with adjusted R&D expenses of €2,200–2,500 million and adjusted SG&A expenses of €700–800 million. BioNTech highlighted a $3.5 billion up‑front and non‑contingent payment and up to $7.6 billion in milestones from its BMS partnership around pumitamig, plans for up to $1.0 billion in share repurchases over twelve months, and manufacturing consolidation measures expected to reach about €500 million in recurring annual savings by 2029.
Positive
- None.
Negative
- None.
Insights
AGM approvals reinforce BioNTech’s oncology focus, backed by strong liquidity and disciplined spending.
BioNTech’s shareholders backed all AGM resolutions, including expanding the Supervisory Board to eight members and electing oncology and commercialization specialists. This aligns with management’s push to commercialize a broad late‑stage cancer pipeline while still monetizing its COVID‑19 franchise.
Financially, 2025 IFRS revenues of €2,870 million exceeded guidance, and Q1 2026 ended with a substantial €16.8 billion cash and securities position. Management reaffirmed 2026 non‑IFRS revenue guidance of €2,000–2,300 million and significant adjusted R&D spending, signaling continued heavy investment in oncology assets.
Capital allocation is notably active: a BMS deal tied to pumitamig includes $3.5 billion in up‑front and non‑contingent payments plus up to $7.6 billion in milestones, while a share repurchase of up to $1.0 billion and manufacturing consolidation targeting roughly €500 million annual savings by 2029 aim to balance growth and returns.
Key Figures
FY 2025 revenues: €2,870 million
FY 2025 R&D expenses: €2,105 million
Q1 2026 revenues: 118 M€
+5 more
8 metrics
FY 2025 revenues
€2,870 million
IFRS results compared to €2,600–2,800 million guidance range
FY 2025 R&D expenses
€2,105 million
IFRS research and development expenses in 2025
Q1 2026 revenues
118 M€
Unaudited revenue for first quarter 2026
Q1 2026 cash and securities
16.8 B€
Cash, cash equivalents and security investments as of March 31, 2026
2026 revenue guidance
€2,000–2,300 million
Non-IFRS full-year 2026 total revenues guidance
BMS pumitamig up-front payments
$3.5 billion
Up-front and non-contingent payments from Bristol Myers Squibb
Pumitamig milestone potential
$7.6 billion
Potential milestone payments under BMS partnership
Target annual savings
€500 million
Expected recurring manufacturing savings upon full implementation in 2029
Key Terms
Authorized Capital 2026, domination and profit and loss transfer agreement, American Depositary Share (ADS), antibody-drug conjugate, +2 more
6 terms
Authorized Capital 2026 financial
"Resolution on the cancellation of the existing Authorized Capital 2025 and the creation of new Authorized Capital 2026"
domination and profit and loss transfer agreement financial
"approval of the conclusion of a domination and profit and loss transfer agreement between BioNTech SE and BioNTech Discovery GmbH"
A domination and profit and loss transfer agreement is a legal contract in which a parent company takes control of a subsidiary’s management decisions while the subsidiary agrees to pass its profits to the parent and have the parent cover its losses. For investors this shifts who bears gains and risks, concentrates decision-making and cash flows, can change how results are reported and taxed, and affects minority shareholder protections—like one household running another’s budget and collecting its surplus while covering any shortfalls.
antibody-drug conjugate financial
"ADCs as potential “augmenters” of immunomodulators and mRNA cancer immunotherapies"
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
non-IFRS measures financial
"BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance"
Non-IFRS measures are financial figures that companies create on their own to show aspects of their performance, beyond what standard accounting rules require. They can help investors better understand how a company is really doing by highlighting information that might be more relevant or easier to interpret, much like a sports coach emphasizes certain stats to showcase team strengths not captured by official scores.
virtual Annual General Meeting financial
"reauthorize the Management Board to provide for the holding of a virtual Annual General Meeting"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MAY 2026
COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of registrant’s name into English)
(Translation of registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
On May 15, 2026, BioNTech SE held the Annual General Meeting (“AGM”) 2026. The press release and the AGM presentation are attached as Exhibits 99.1 and 99.2, respectively. The voting results are attached as Exhibit 99.3.
SIGNATURE
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BioNTech SE | ||||||||||||||
By: | /s/ Ramón Zapata Gomez | By: | /s/ Dr. Sierk Poetting | |||||||||||
Name: Ramón Zapata Gomez | Name: Dr. Sierk Poetting | |||||||||||||
Title: Chief Financial Officer | Title: Chief Operating Officer | |||||||||||||
Date: May 15, 2026
EXHIBIT INDEX
Exhibit | Description of Exhibit | ||||
99.1 | Press Release: BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 | ||||
99.2 | Annual General Meeting 2026 Presentation | ||||
99.3 | Annual General Meeting 2026 Voting Results | ||||
Exhibit 99.1
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the virtual assembly. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a majority of the shareholders.
BioNTech is strengthening its focus on the Company’s growing late-stage oncology pipeline, while continuing its discovery and early research aimed at long-term innovation. Consequently, the Company's shareholders approved expanding the Supervisory Board from six to eight members and adding additional expertise: Prof. Iris Löw-Friedrich, M.D., Ph.D., and Susanne Schaffert, Ph.D., were elected as new members of the Supervisory Board.
Iris Löw-Friedrich has many years of expertise in the field of clinical development and broad experience in the scientific and medical fields. She also possesses knowledge in the areas of sales and commercialization, management, innovation, and international markets relevant to the Company.
She is an experienced Supervisory Board member and adjunct professor of internal medicine at the faculty of medicine at Goethe University in Frankfurt am Main, Germany.
Susanne Schaffert is a member of supervisory boards in the healthcare sector, including that of Merck KGaA. She possesses particular expertise in the field of oncology as well as in sales and commercialization with a focus on product launches. Her knowledge spans innovation, research and development, and organizational leadership and management.
Additionally, shareholders approved the extension of the mandates of BioNTech’s Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, Ph.D., and Prof. Rudolf Staudigl, Ph.D.
At a meeting held following the AGM, the Supervisory Board elected Helmut Jeggle as its Chairman.
The voting results for all agenda items can be viewed on the Annual General Meeting 2026 website under the section ‘Voting Results’. The speeches by Chief Executive Officer Prof. Ugur Sahin, M.D., Chief Financial Officer Ramón Zapata and the slides presented at the AGM 2026 can be found in section ‘Speeches and Presentations’ under the same link.
About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit www.BioNTech.com.
BioNTech Forward-Looking Statements
1
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the potential benefits of appointed Supervisory Board members. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements.
You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
CONTACTS
Investor Relations
Douglas Maffei, PhD
Investors@biontech.de
Media Relations
Jasmina Alatovic
Media@biontech.de
2
Annual General Meeting 15 May 2026, 14:00 CEST Exhibit 99.2
Operations Development 2025 & Q1 2026 and Outlook 2026 Prof. Dr. Uğur Şahin, Co-Founder & Chief Executive Officer Financial Development 2025 & Q1 2026 and Financial Outlook 2026 Ramón Zapata, Chief Financial Officer 1 2 2 Management Report
Operations Development 2025 & Q1 2026 and Outlook 2026 Prof. Dr. Uğur Şahin, Co-Founder & Chief Executive Officer 1 3
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech’s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech’s expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; BioNTech’s expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech’s expectations with respect to intellectual property; the impact of BioNTech’s collaboration and licensing agreements, including BioNTech’s partnership with BMS; BioNTech's expectations with respect to developments in law, public policy, and international trade; BioNTech’s estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech’s expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward- looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this presentation, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech’s pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech’s other product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech’s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. Furthermore, certain statements contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and BioNTech’s own internal estimates and research. While BioNTech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, any market data included in this presentation involves assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. While BioNTech believes its own internal research is reliable, such research has not been verified by any independent source. In addition, BioNTech is the owner of various trademarks, trade names and service marks that may appear in this presentation. Certain other trademarks, trade names and service marks appearing in this presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this presentation may be referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. 4 An abbreviation directory of defined terms can be found at the end of the presentation. To be updated by Legal This Slide Presentation Includes Forward-Looking Statements
COVID-19 Vaccine Global Impact Addressing Oncology Unmet Medical Need Focused Infectious Disease Innovation 5 Billion vaccine doses distributed1 >25 Ongoing Phase 2 & Phase 3 trials2 17 Clinical programs3 7 High unmet need clinical programs4 Continuing to Execute on BioNTech’s Strategy 5 1. Includes globally distributed doses from 2020 to-date; 2. Includes Phase 2 or 3 trials for BNT113, autogene cevumeran, gotistobart, trastuzumab pamirtecan and pumitamig; 3. Includes BNT113, BNT116, autogene cevumeran, BNT211, BNT314/GEN1059, gotistobart, BNT317, trastuzumab pamirtecan, BNT324/DB-1311, BNT325/DB-1305, BNT326/YL202, pumitamig, BNT329, BNT3212, BNT3213; BNT3214; 4. Includes BNT162, BNT161, BNT163, BNT164. BNT165, BNT166, BNT351; Numbers on the slide are as of 5 May 2026. In-House GMP Manufacturing Platforms Fully Integrated AI-Driven Innovation Capabilities and facilities for key platforms: mRNA therapeutics, including individualized mRNA and bispecific antibodies Tech-bio company with AI-infused target and drug discovery and development capabilities
2025 Achievements: Strong Performance and Pipeline Momentum 6 1. Over 50%, including Italy, Spain, France, Germany, USA, Japan, Australia. COVID-19 Market Leadership1 Advanced Key Oncology Programs Executed Key Strategic Deals Strengthened Financial Position
Strategic Oncology Multi-Modal Immunotherapy Approach 7 1. Synergistic potential Space for curative approaches Immunomodulators Targeted therapies Synergy1Synergy1 Synergy1 mRNA cancer immunotherapies • Precise and potent modalities for fast onset tumor reduction • ADC as potential “augmenters” of immunomodulators and mRNA cancer immunotherapies • HER2, TROP2, B7H3, HER3, and EGFR/HER3 ADCs as combination partners • Focus on the critical IO pathways • Targeting different complementary pathways in cancer immunity cycle may promote a durable anti-tumor effect • Eliminate polyclonal residual disease with multi-antigen and individualized approaches • Polyspecific activity by targeting multiple antigens at once • Establish long-lasting immunological memory to prevent relapses
Innovative BMS Partnership Structured to Accelerate and Maximize Pumitamig’s Potential 8 Maximizing potential of next-generation PD-L1xVEGF-A bispecific antibody, pumitamig, with global co-development and co-commercialization BMS partnership Seven global registrational trials for pumitamig ongoing 50/50 partnership and cost sharing structure de-risks R&D activities $3.5 billion up-front and non-contingent payments + $7.6 billion in milestone payments1 Anti-PD-L1 Anti-VEGF-A More information can be found in BioNTech’s Annual Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, as amended, which is available at www.sec.gov.
BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs 9 1. Partnered with Bristol Myers Squibb Leveraging novel combinations to maximize pipeline potential and elevate solid tumor treatment outcomes Lung Breast Genitourinary Gastrointestinal Gynecologic Additional Tumors Pumitamig1 ADC IO mRNA
Building a Multi-Product Company by 2030 Targeting 17+ Late-Stage/Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities 10 1. Expected data readouts may be from interim or final analyses and are event-driven, and in some cases may not translate into commercial launches; Partnered with 2. Bristol Myers Squibb; 3. OncoC4; 4. DualityBio; 5. Genentech, a member of the Roche group; 6. These are Phase 1/2 trials. The anticipated pivotal trials evaluating pumitamig in these tumor types are expected to readout after 2030. Tumor Type Assets Expected Data Readouts1 2026 2027 2028 2029 2030+ Lung 1L NSCLC Pumitamig2 Stage III unresectable NSCLC Pumitamig2 1L NSCLC – PD-L1 ≥ 50% Pumitamig2 2L+ sqNSCLC1 Gotistobart3 1L ES-SCLC Pumitamig2 Breast 1L TNBC – all comers Pumitamig2 1L TNBC – CPS < 10 Pumitamig2 2L+ HR+ BC1 – HER2-low Trastuzumab pamirtecan4 Genitourinary 1L RCC Pumitamig2,6 1L CRPC BNT324/DB-13114 Gastrointestinal 1L MSS-CRC Pumitamig2 1L Gastric – HER2-neg, PD-L1+ Pumitamig2 1L HCC Pumitamig2,6 Adj. CRC - ctDNA+ Autogene cevumeran5 Adj. PDAC Autogene cevumeran5 Gynecologic 2L+ Endometrial1 – HER2-expressing Trastuzumab pamirtecan4 Trastuzumab pamirtecan4 Additional Tumors 1L HNSCC – PD-L1 CPS ≥ 1, HPV16+ BNT113
Our Mission We are committed to improving the health of people worldwide with our fundamental research and work in the development of immunotherapies. Our Vision We aspire to harness the power of the immune system to develop novel therapies against cancer, infectious diseases and other severe diseases. We believe in scientific rigor, innovation and passion as driving forces.Our vision and mission have not changed since the founding of BioNTech. 11
Financial Development 2025 & Q1 2026 and Financial Outlook 2026 Ramón Zapata, Chief Financial Officer 2 12
Full Year 2025 Financial Results Compared to Guidance 13 1. All numbers have been rounded. More information can be found in BioNTech’s Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, as amended, which is available at www.sec.gov. In € millions FY 2025 IFRS Results1 FY 2025 IFRS Guidance Total Revenues 2,870 2,600 – 2,800 R&D Expenses 2,105 2,000 – 2,200 SG&A Expenses 624 550 – 650 Capital Expenditures for Operating Activities 198 200 – 250
First Quarter 2026 Unaudited Financial Results Highlights1 14 1. All numbers have been rounded. 2. In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix “Adjusted” or, as a whole, “Adjusted Results”). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech’s non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Cash and cash equivalents plus security investments as of March 31, 2026, reached €16,763.3 million, comprising €9,939.4 million in cash and cash equivalents, €4,696.9 million in current security investments disclosed as financial assets and €2,127.0 million in non-current security investments disclosed as financial assets. 118 M€ Revenues Adjusted Research & Development Expenses2 (IFRS: 557 M€) 527 M€ Sales, Marketing, General & Administrative Expenses 151 M€ Cash and Cash Equivalents plus Security Investments3 16.8 B€
Reaffirming Full Year 2026 Financial Guidance1 15 1. Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions (“M&A”) transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. In € millions FY 2026 non-IFRS Guidance Total Revenues 2,000 – 2,300 Adjusted R&D Expenses 2,200 – 2,500 Adjusted SG&A Expenses 700 – 800 Revenue Guidance Considerations • Competitive market dynamics in the United States • Begin managing transition away from multi-year contracts in Europe, and specifically in Germany where BioNTech recognizes direct sales for its COVID-19 vaccine • Stable revenues from the collaboration with BMS, from a pandemic preparedness contract with the German government, and from the BioNTech Group service businesses • No operationally-driven one-time revenue effect, such as from Pfizer opt-out from further development of shingles program
Capital Transactions During Full Year 2025 and First Quarter 2026 16 Use of ADSs1 held in treasury Period Number of issued ADSs Percentage of share capital2 Issue price Volume3 Biotheus Founder SBP Program January 2025 421,818 0.16% €116.58 €49.2 million ESOP 2018 Settlement March to December 2025 24,147 0.01% €91.68 €2.2 million LTI 2020 Settlement April to June 2025 636 < 0.01% €112.10 €0.1 million InstaDeep Tranche 2 Settlement July 2025 49,143 0.02% €93.92 €4.6 million LTI 2024 Tranche 1 Settlement December 2025 229,870 0.09% €81.90 €18.8 million LTI 2021 Settlement December 2025 96,424 0.04% €81.10 €7.8 million Total number of used ADSs previously held in treasury 822,038 0.32% Ø €100.63 €82.7 million Employee Participation Programs Issuance of new ADSs or use of ADSs1 held in treasury Period Number of issued ADSs Percentage of share capital2 Issue price or fair value Volume3 First and Second Offer Period (issuance) December 2025 10,475,287 4.04% €82.905 €868.4 million Post-Offer Reorganization (held in treasury) January 2026 1,552,300 0.60% €82.90 €128.7 million4 Total number of ADSs 12,027,587 4.64% Ø €82.90 €997.1 million Acquisition of CureVac 1. American Depositary Share (ADS), each representing one ordinary share. 2. The "percentage of share capital" ratio is calculated based on the shares issued as of December 31, 2025 and as of March 31, 2026 (both 259,027,487), respectively. 3. Numbers have been rounded. 4. Disclosed as an obligation to issue share capital in BioNTech’s Annual Report on Form 20-F as of and for the year ended December 31, 2025. Post-offer reorganization took place in Q1 2026. Withholding tax of €4.0 million was paid during the post-offer reorganization in Q1 2026 in cash (“withhold to cover” for approx. 48,000 ADSs). 5. Fair value of $96.73 per ADS, calculated using the exchange rate of 0.86. Use of ADSs1 held in treasury Period Number of issued ADSs Percentage of share capital2 Issue price Volume3 CureVac Transaction Award December 2025 57,211 0.02% €78.75 €4.5 million Total number of used ADSs previously held in treasury 57,211 0.02% €78.75 €4.5 million
Capital Transactions During Full Year 2025 and First Quarter 2026 17 1. American Depositary Share (ADS), each representing one ordinary share. 2. The "percentage of share capital" ratio is calculated based on the shares issued as of March 31, 2026 (259,027,487). 3. Numbers have been rounded. Use of ADSs1 held in treasury Period Number of issued ADSs Percentage of share capital2 Issue price Volume3 LTI 2021 Settlement February 2026 169 < 0.01% €81.10 €0.01 million ESOP 2018 Settlement March 2026 6,452 < 0.01% €78.07 €0.5 million Total number of used ADSs previously held in treasury 6,621 < 0.01% Ø €78.15 €0.51 million Employee Participation Programs
Focused Capital Allocation Strategy for Sustainable Value Creation 18 1. Expected savings relative to BioNTech's 2025 cost base and CureVac's 2026 budget; do not reflect partially offsetting costs for CDMO use or transfer to other sites; and exclude exit costs, which will be recorded as incurred. Focusing R&D Investments Concentrate investments on advancing BioNTech’s growing oncology pipeline toward commercialization, including pumitamig and ADC candidates Announced Share Repurchase Program Initiating share repurchase program of up to $1.0 billion over the next twelve months Manufacturing Footprint Consolidation Enhance operational efficiency with expected cost savings to ramp up over time, reaching approximately €500 million in recurring annual savings upon full implementation of the measures in 20291
19 Advanced Strategy, Matured Pipeline and De-risked Development Drive Oncology Execution at Scale and Speed Diversified Multi- Product Company Progress key programs into pivotal stage, leverage partnership with BMS, fortified balance sheet to fund our pipeline Advance combination therapy studies, accelerate pivotal trial execution, build indication-specific oncology portfolios and execute oncology launches Build a diversified, multi-product global immunotherapy powerhouse addressing high unmet medical need of cancer patients worldwide Today 2026-2029 2030 BioNTech Oncology Vision: Translating Science into Survival
Thank you
Reconciliation of IFRS to Adjusted Results – Q1 2026 & 2025 Financial Results In € millions except per share data1 Q1 2026 (unaudited) Q1 2025 (unaudited) IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 118 - 118 183 - 183 Cost of sales (71) - (71) (84) - (84) Research and development expenses (557) 30 (527) (526) - (526) Sales, marketing, general and administrative expenses (151) - (151) (121) - (121) Other operating result (16) 7 (9) 13 (15) (2) Operating loss (677) 37 (640) (534) (15) (549) Net loss3 (532) 37 (495) (416) (15) (431) Basic and diluted loss per share (2.10) (1.95) (1.73) (1.79) 1. All Numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix “Adjusted” or, as a whole, “Adjusted Results”). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech’s measures based on IFRS Accounting Standards and more information can be found in BioNTech’s Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech’s non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Tax effects are not considered as part of BioNTech’s non-IFRS adjustments. 21
22 n L nth line DNA Desoxyribonucleic acid (sq) NSCLC (squamous) Non-small cell lung cancer ADC Antibody-drug conjugate EGFR Epidermal growth factor receptor P&L Profit and loss statement adj. Adjuvant ESOP Employee stock ownership plan PD-L1 Programmed cell death protein ligand 1 ADS American Depositary Shares FY Fiscal year PDAC Pancreatic ductal adenocarcinoma AI Artificial intelligence GMP Good Manufacturing Practice Q1 First quarter B7H3 B7 Homolog 3 HCC Hepatocellular carcinoma R&D Research and development BC Breast cancer HER2 (3) Human epidermal growth factor RCC Renal cell carcinoma BMS Bristol Myers Squibb receptor 2 (3) SBP Share-based payment CDMO Contract Development and HNSCC Head and neck squamous cell carcinoma (ES)SCLC (Extensive stage) small cell lung cancer Manufacturing Organization HPV 16 Human papilloma virus 16 SEC Securities and Exchange Commission CEPI Coalition for Epidemic HR Hormone receptor SG&A Selling, general and administrative Preparedness Innovations IFRS International financial reporting standards expenses CPS Combined positive score IO Immuno-oncology TNBC Triple-negative breast cancer CRC Colorectal cancer LTI Long-term incentive TROP2 Trophoblast cell-surface antigen 2 CRPC Castration resistant prostate cancer mRNA Messenger ribonucleic acid VEGF-A Vascular endothelial growth factor A ctDNA Circulating tumor DNA MSS Microsatellite stability Abbreviation Directory
Voting results - Overview BioNTech SE, Mainz ordinary Annual General Meeting on 15/05/2026 Page 1Note: Percentages rounded to 2 decimal places Valid votes cast Yes votes No votes Item Shares % of capital stock Shares % Shares % Item 2 Resolution on the appropriation of the balance sheet profit for the 2025 financial year 234,799,767 90.65 % 234,734,083 99.97 % 65,684 0.03 % adopted Item 3 Resolution on the approval of the actions of the Management Board 198,284,335 76.55 % 197,873,174 99.79 % 411,161 0.21 % adopted Item 4 Resolution on the approval of the actions of the Supervisory Board 236,818,981 91.43 % 236,071,180 99.68 % 747,801 0.32 % adopted Item 5 Resolution on the appointment of the auditor and the Group auditor for the 2026 financial year and the auditor for any audit or review of interim reports 238,289,587 91.99 % 237,926,738 99.85 % 362,849 0.15 % adopted Item 6 Resolution on the approval of the Compensation Report 238,280,961 91.99 % 230,176,677 96.60 % 8,104,284 3.40 % adopted Item 7 Resolution on the amendment of Section 9 para. 1 of the Articles of Association to increase the size of the Supervisory Board 238,286,403 91.99 % 238,238,932 99.98 % 47,471 0.02 % adopted Item 8.1 Resolution on Elections to the Supervisory Board - Helmut Jeggle 238,286,432 91.99 % 236,945,474 99.44 % 1,340,958 0.56 % adopted Item 8.2 Resolution on Elections to the Supervisory Board - Prof. Dr. Anja Morawietz 238,288,562 91.99 % 238,000,533 99.88 % 288,029 0.12 % adopted Item 8.3 Resolution on Elections to the Supervisory Board - Prof. Dr. Rudolf Staudigl 238,289,153 91.99 % 235,551,089 98.85 % 2,738,064 1.15 % adopted Item 8.4 Resolution on Elections to the Supervisory Board - Dr. Susanne Schaffert 238,288,876 91.99 % 238,242,633 99.98 % 46,243 0.02 % adopted Item 8.5 Resolution on Elections to the Supervisory Board - Prof. Dr. Iris Loew-Friedrich 238,288,266 91.99 % 216,215,291 90.74 % 22,072,975 9.26 % adopted Exhibit 99.3
Voting results - Overview BioNTech SE, Mainz ordinary Annual General Meeting on 15/05/2026 Page 2Note: Percentages rounded to 2 decimal places Valid votes cast Yes votes No votes Item Shares % of capital stock Shares % Shares % Item 9 Resolution on the amendment of Section 16 para. 5 of the Articles of Association to reauthorize the Management Board to provide for the holding of a virtual Annual General Meeting 238,288,290 91.99 % 217,903,070 91.45 % 20,385,220 8.55 % adopted Item 10 Resolution on the cancellation of the existing Authorized Capital 2025 and the creation of new Authorized Capital 2026 with the possibility of excluding subscription rights and corresponding amendment to the Articles of Association 238,290,388 91.99 % 236,478,038 99.24 % 1,812,350 0.76 % adopted Item 11 Resolution on the approval of the conclusion of a domination and profit and loss transfer agreement between BioNTech SE and BioNTech Discovery GmbH 238,284,305 91.99 % 237,836,243 99.81 % 448,062 0.19 % adopted
FAQ
How did BioNTech (BNTX) perform financially in full-year 2025 versus guidance?
BioNTech reported 2025 IFRS revenues of €2,870 million, slightly above its guidance range of €2,600–2,800 million. IFRS R&D expenses were €2,105 million versus a guided €2,000–2,200 million, and SG&A expenses were €624 million, within the €550–650 million guidance, reflecting heavy investment yet controlled operating costs.
What are BioNTech’s (BNTX) key first quarter 2026 financial highlights?
In Q1 2026, BioNTech generated revenues of €118 million and reported adjusted R&D expenses of €527 million, compared with IFRS R&D expenses of €557 million. Sales, marketing, general and administrative expenses were €151 million. Cash, cash equivalents and security investments together reached about €16.8 billion, providing substantial financial flexibility.
What 2026 financial guidance has BioNTech (BNTX) reaffirmed?
For 2026, BioNTech reaffirmed non‑IFRS revenue guidance of €2,000–2,300 million. Adjusted R&D expenses are projected at €2,200–2,500 million and adjusted SG&A expenses at €700–800 million. Guidance reflects ongoing oncology pipeline investment, evolving COVID‑19 vaccine demand, and contributions from collaborations and preparedness contracts.
What are the main terms of BioNTech’s (BNTX) pumitamig partnership with Bristol Myers Squibb?
The pumitamig partnership with Bristol Myers Squibb features global co‑development and co‑commercialization of the PD‑L1xVEGF‑A bispecific antibody. BioNTech highlighted $3.5 billion in up‑front and non‑contingent payments plus up to $7.6 billion in milestone payments, alongside a 50/50 cost‑sharing structure that reduces development risk.